NCT01024101View on ClinicalTrials.gov

Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Head and Neck Cancer
Interventions
DRUG

Paclitaxel

Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY